A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies

Tyrosine kinase inhibitors (TKI) have improved CML response rates, and some are effective against resistance-promoting point mutations in BCR-ABL1. However, in the absence of point mutations, resistance still occurs. Here, we identify a novel pathway mediating resistance which connects p47phox, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Irwin, Mary E., Johnson, Blake P., Manshouri, Roxsan, Amin, Hesham M., Chandra, Joya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695141/
https://www.ncbi.nlm.nih.gov/pubmed/26136341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695141/
https://www.ncbi.nlm.nih.gov/pubmed/26136341

Ejemplares similares